# US Viral Vectors and Plasmid DNA Manufacturing Market > US Viral Vectors and Plasmid DNA Manufacturing Market Research Report By Vector Type (Plasmid DNA, Viral Vector, Non-viral Vector), By Disease Type (Cancer, Genetic Disorder, Infectious Disease), By Application (Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology, Research), By Workflow (Upstream Processing, Downstream Processing) and By End-User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 13.26% - **2024:** $ 112 Million - **2025:** $ 126.85 Million - **2035:** $ 440.7 Million - **Key Players:** Lonza Group (CH), Sartorius AG (DE), Thermo Fisher Scientific (US), Merck KGaA (DE), Boehringer Ingelheim (DE), Cobra Biologics (GB), Viva Biotech (CN), GenScript Biotech (CN), Abcam plc (GB) **Report ID:** MRFR/HC/18205-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-viral-vectors-and-plasmid-dna-manufacturing-market-19752 --- ## Market Summary ## **US Viral Vectors and Plasmid DNA Manufacturing Market Overview** As per MRFR analysis, the US Viral Vectors and Plasmid DNA Manufacturing Market Size was estimated at 105 (USD Million) in 2023. The US Viral Vectors and Plasmid DNA Manufacturing Market Industry is expected to grow from 120(USD Million) in 2024 to 479.45 (USD Million) by 2035. The US Viral Vectors and Plasmid DNA Manufacturing Market CAGR (growth rate) is expected to be around 13.419% during the forecast period (2025 - 2035). ### **Key US Viral Vectors and Plasmid DNA Manufacturing Market Trends Highlighted** The US Viral Vectors and Plasmid DNA Manufacturing Market is experiencing significant growth fueled by several key market drivers. An increasing number of gene therapy and vaccine development initiatives, supported by robust funding from government bodies like the National Institutes of Health (NIH) and the Department of Defense, are propelling the demand for viral vectors and plasmid DNA. The urgency to develop innovative therapies for conditions such as cancer and rare genetic disorders further emphasizes the need for efficient manufacturing processes in this sector. Additionally, the push towards personalized medicine is driving research institutions and biopharmaceutical companies to explore advanced manufacturing techniques, highlighting the importance of scalability and regulatory compliance in production. Opportunities are emerging as the US continues to prioritize biomanufacturing within its strategic plans. Initiatives aimed at strengthening domestic supply chains for critical healthcare materials open avenues for local manufacturers to enhance their capabilities in producing high-quality viral vectors and plasmid DNA. The establishment of collaborative efforts between private industry and public research institutions can address the increasing complexities associated with the production process, especially in meeting stringent regulatory requirements set by the U.S. Food and Drug Administration. In recent times, there has been a notable trend towards adopting automation and advanced technologies. This adoption not only streamlines the production processes but also improves the consistency and quality of outputs, aligning with the stringent demands of the pharmaceutical industry. As the US continues to advance in biotechnology, staying alert to these evolving market trends is essential for stakeholders to seize opportunities effectively and foster sustainable growth within the Viral Vectors and Plasmid DNA Manufacturing landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Viral Vectors and Plasmid DNA Manufacturing Market Drivers** ### **Increasing Demand for Gene Therapies** The rapid growth in the field of gene therapies is significantly fueling the US [Viral Vectors and Plasmid DNA Manufacturing Market](../../../reports/viral-vectors-and-plasmid-dna-manufacturing-market-10679) Industry. According to the FDA, there has been a notable increase in the approvals of gene therapies, rising from just 2 approvals in 2015 to 21 in 2020. This trend implies a growing investment in gene therapies, which rely heavily on viral vectors and plasmid DNA. Companies like Novartis and Gilead are increasingly investing in better manufacturing technologies to streamline production, reflecting the industry's shift towards innovative biological therapies. This uptick in gene therapy applications is expected to drive the demand for advanced manufacturing processes, thus boosting the market. ### **Rise in Cancer Incidence Rates** The US is witnessing an alarming increase in cancer incidence, which directly impacts the demand for innovative treatment solutions like viral vectors and plasmid DNA for vaccine and therapy development. The American Cancer Society reported that an estimated 1.9 million new cancer cases are expected to be diagnosed in 2021 alone, highlighting a substantial need for targeted therapies. Organizations such as Amgen and Kite Pharma are focusing on harnessing viral vectors in their cancer therapies, thereby increasing manufacturing requirements. This growing sector indicates a solid foundation for the US Viral Vectors and Plasmid DNA Manufacturing Market Industry's expansion. ### **Advancements in Manufacturing Technologies** The emergence of novel manufacturing technologies is reshaping the US Viral Vectors and Plasmid DNA Manufacturing Market Industry. Recent developments such as the adoption of continuous manufacturing processes can improve efficiency and reduce costs associated with production. For instance, major biotechnology companies like Regeneron and Amgen are implementing advanced production techniques that allow for expedited manufacturing timelines. These innovations in technologies not only increase productivity but also enhance the scalability of production, catering to the rapidly growing market demands for viral vectors and plasmid DNA, especially in therapeutic applications. ### **Government Initiatives and Funding** Government support plays a crucial role in propelling the US Viral Vectors and Plasmid DNA Manufacturing Market Industry forward. The National Institutes of Health (NIH) and the National Cancer Institute have significantly increased their funding for Research and Development initiatives focused on gene therapy. In 2020, the NIH allocated over USD 400 million towards gene therapy research initiatives. This robust financial backing encourages innovation and development within the sector, leading to increased manufacturing activities. Initiatives such as the Advanced Research Projects Agency–Health aim to expedite the integration of medical technologies, providing a fertile ground for growth in the viral vector and plasmid DNA manufacturing segment. ## **US Viral Vectors and Plasmid DNA Manufacturing Market Segment Insights** ### **Viral Vectors and Plasmid DNA Manufacturing Market Vector Type Insights** The US Viral Vectors and Plasmid DNA Manufacturing Market, particularly focused on the Vector Type segment, showcases significant growth potential and strategic advancements in biopharmaceutical applications. This segment encompasses diverse methodologies of gene delivery, segmented into Plasmid DNA, Viral Vectors, and Non-viral Vectors, each with its own unique attributes and applications. Plasmid DNA has emerged as a crucial component in the development of DNA vaccines and gene therapies, which are increasingly in demand due to rising incidences of genetic disorders and infectious diseases in the United States. Viral Vectors are of paramount importance in gene therapy due to their efficiency in delivering therapeutic genes to target cells, which enhances their utility in treating complex conditions such as cancer and genetic diseases. This delivery system harnesses the natural ability of viruses to enter cells, thereby making it a dominant player in innovative treatment modalities. Furthermore, Non-viral Vectors are gaining traction as a safer alternative for gene delivery. They eliminate the risk associated with viral infection and have shown promising results in Research and Development (R&D) for gene-editing techniques, including CRISPR technology. The trends in the US market underscore a strong inclination towards personalized medicine, where the integration of these Vector Types complements the rising focus on targeted therapies that cater to individual patient profiles. The advancements in manufacturing technologies and the increasing investment in R&D activities are anticipated to fortify the production capabilities and optimize the efficacy of these vectors. The collaboration between biotechnology firms and academic institutions is another factor driving the continuous evolution of these vectors, fostering an environment ripe for innovation. As the landscape of gene therapy continues to expand, the Vector Type segment will play a pivotal role in shaping the future of the US Viral Vectors and Plasmid DNA Manufacturing Market, ensuring high-quality products that are aligned with the growing healthcare demands. In summary, the importance of Vector Types in the US serves as a backbone connecting various therapeutic avenues, highlighting the market's dedication to pioneering advanced solutions for health challenges prevalent in the region. The strong alignment of public health policies and funding initiatives, aimed at gene therapies, supports a fertile ground for the growth of this segment, ultimately enhancing the overall productivity and efficacy of the US Viral Vectors and Plasmid DNA Manufacturing Market. The evolving market landscape is indicative of a broader movement towards harnessing the potential of genetic-based treatments, underlining the critical role that the Vector Type segment has in driving advancements in this field. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Viral Vectors and Plasmid DNA Manufacturing Market Disease Type Insights** The US Viral Vectors and Plasmid DNA Manufacturing Market, when segmented by Disease Type, presents a varied landscape driven by significant health challenges. The cancer treatment segment has seen substantial advancements, utilizing viral vectors to enhance targeted therapies that show promising potential for personalized medicine in oncology. Similarly, the Genetic Disorder segment leverages these manufacturing technologies to deliver gene therapies that address rare and inherited diseases, reflecting a growing focus on precision medicine and innovative treatment modalities. Infectious Diseases also represent a crucial area, where viral vectors are increasingly utilized in vaccine development, notably highlighted during public health initiatives to combat global pandemics. The ongoing collaboration between biotechnology companies, research institutions, and healthcare providers in the US drives innovation in these areas, ensuring that cutting-edge therapies remain at the forefront of the medical landscape. Overall, the dynamic shifts and innovations within these segments underscore their vital role in shaping the future of treatment options in the US healthcare system, emphasizing both clinical efficacy and patient accessibility. ### **Viral Vectors and Plasmid DNA Manufacturing Market Application Insights** The US Viral Vectors and Plasmid DNA Manufacturing Market under the Application segment encompasses a variety of crucial areas such as Antisense and RNA interference Therapy, Gene Therapy, Cell Therapy, Vaccinology, and Research. Each application plays a vital role in advancing therapeutic developments and techniques in the healthcare sector. Antisense and RNA interference Therapy is particularly significant for its ability to modulate gene expression, offering innovative treatments for various genetic disorders. Gene Therapy represents a transformative approach in treating inherited conditions and tumors by replacing defective genes with functional ones. Cell Therapy, gaining momentum, utilizes living cells to treat diseases, including cancers and degenerative conditions. Vaccinology, critical for disease prevention, benefits from advancements in viral vectors, facilitating the development of effective vaccines, especially in response to recent global health crises. Lastly, the Research sector significantly contributes to understanding genetic mechanisms, unraveling new therapies, and enhancing existing ones. As the healthcare landscape evolves, the Application segment's prominence within the US Viral Vectors and Plasmid DNA Manufacturing Market reflects the ongoing innovations aimed at addressing unmet medical needs and improving patient outcomes. ### **Viral Vectors and Plasmid DNA Manufacturing Market Workflow Insights** The Workflow segment of the US Viral Vectors and Plasmid DNA Manufacturing Market is critical for facilitating the production of advanced therapies and vaccines. This segment can be divided into two key areas: Upstream Processing and Downstream Processing. Upstream Processing plays a vital role in the initial stages of viral vector and plasmid DNA production, focusing on the cultivation of cells that produce these biological materials. This area has gained traction due to advancements in cell culture technologies and bioreactors, allowing for increased yield and efficiency. On the other hand, Downstream Processing encompasses purification and formulation steps, ensuring that the final product meets quality standards for safety and efficacy. It is significant as it directly impacts the overall purity and stability of viral vectors and plasmids, essential for successful therapeutic applications. As the demand for gene therapies and vaccines rises, especially in the US, the Workflow segment is expected to meet these challenges while driving innovation and research efforts, thus highlighting its importance in the overall market dynamics. Increasing investments in biomanufacturing facilities in the US will further bolster the performance of both Upstream and Downstream Processing activities, contributing to the growth trajectory of the US Viral Vectors and Plasmid DNA Manufacturing Market. ### **Viral Vectors and Plasmid DNA Manufacturing Market End-User Insights** The End-User segment of the US Viral Vectors and Plasmid DNA Manufacturing Market plays a pivotal role in advancing therapeutic innovations. Within this segment, Pharmaceutical and Biopharmaceutical Companies constitute a significant portion, driven by an increasing demand for personalized medicine and gene therapies. This sector focuses on developing advanced treatment options, contributing to enhanced patient outcomes and driving the growth of the overall market. Research Institutes are also vital players in this arena, as they frequently engage in cutting-edge studies and clinical trials that underpin new product developments. Their collaborative efforts with the commercial sector help in translating research breakthroughs into viable therapies. The synergy between these players promotes a dynamic environment for innovation, reflecting the importance of the End-User segment in addressing public health challenges. As investments in R&D expand, the demand for tailored therapeutic solutions continues to rise, further cementing the significance of the US Viral Vectors and Plasmid DNA Manufacturing Market. This ongoing trend emphasizes the critical nature of these End-Users in shaping the future of healthcare solutions in the US. ## **US Viral Vectors and Plasmid DNA Manufacturing Market Key Players and Competitive Insights** The US Viral Vectors and Plasmid DNA Manufacturing Market is a rapidly evolving segment of the biopharmaceutical industry that focuses on the production of viral vectors and plasmid DNA, which are essential components in gene therapy and vaccine development. As the demand for innovative therapies increases, the market is becoming increasingly competitive, with numerous players striving to enhance their capabilities to meet the needs of biopharmaceutical companies. The growth of advanced manufacturing technologies and the rising investment in gene therapies significantly contribute to the expanding market landscape. Competitive insights within this sector reveal strategic initiatives driven by innovation, partnerships, and a strong focus on quality to capture market share and facilitate the transition from research and development to commercial-scale production. ### **Key Company Analysis** #### **Cobra Biologics** Cobra Biologics has established a prominent presence within the US Viral Vectors and Plasmid DNA Manufacturing Market, leveraging its extensive experience in the production of plasmid DNA and viral vector products. The company has built its reputation on delivering high-quality materials that meet stringent regulatory requirements, proving to be a reliable partner for biotech and pharmaceutical companies. Cobra Biologics emphasizes scalable manufacturing processes, which allows them to effectively support clients at various stages of the product lifecycle, from clinical trials to commercial production. The firm is also known for its commitment to customer service and collaboration, enabling it to foster strong partnerships with businesses focusing on gene and cell therapies. This customer-centric approach reinforces its position in the market, setting it apart from competitors. #### **Rentschler Biopharma** Rentschler Biopharma represents a key player in the US Viral Vectors and Plasmid DNA Manufacturing Market by offering a wide array of services and expertise in biopharmaceutical development. The company excels in the production of plasmid DNA and viral vectors, catering especially to the needs of gene therapy and vaccine developers. Rentschler Biopharma's strength lies in its advanced manufacturing capabilities and rigorous quality assurance measures that ensure top-tier products. Notably, the company has strategically engaged in mergers and acquisitions to enhance its technological prowess and expand its service offerings. This has positioned Rentschler Biopharma as a competitive contender in the marketplace. Their approach encompasses not only manufacturing efficacy but also a keen focus on optimizing processes and reducing timelines, which is vital for their clients in navigating the highly competitive and fast-paced landscape of the biopharmaceutical industry in the US. ### **Key Companies in the US Viral Vectors and Plasmid DNA Manufacturing Market Include** ## **US Viral Vectors and Plasmid DNA Manufacturing Market Industry Developments** Recent developments in the US Viral Vectors and Plasmid DNA Manufacturing Market are characterized by significant growth and advancements. Companies such as Lonza and Merck have continued to expand their production capacities to meet the increasing demand for gene therapies and vaccines, particularly in light of the COVID-19 pandemic. In August 2023, Cobra Biologics announced the expansion of its facilities to enhance production capabilities for plasmid DNA, which is vital for mRNA vaccine development. In September 2023, Rentschler Biopharma completed the acquisition of a Canadian cGMP plasmid DNA production facility to bolster their offerings in viral vector manufacturing. Moreover, Amgen and Pfizer have been investing heavily in Research and Development efforts focused on novel therapies, resulting in an uptick in market valuation for firms engaged in this sector. Notably, regulatory frameworks in the US have evolved to streamline the approval processes for therapeutics, positioning the market for further growth. Over the last two to three years, major collaborations and public-private partnerships have also been fostered, enhancing innovation in gene therapy manufacturing, which is pivotal for addressing unmet medical needs. ## **US Viral Vectors and Plasmid DNA Manufacturing Market Segmentation Insights** ### **Viral Vectors and Plasmid DNA Manufacturing Market Vector Type Outlook** ### **Viral Vectors and Plasmid DNA Manufacturing Market Disease Type Outlook** ### **Viral Vectors and Plasmid DNA Manufacturing Market Application Outlook** ### **Viral Vectors and Plasmid DNA Manufacturing Market Workflow Outlook** ### **Viral Vectors and Plasmid DNA Manufacturing Market End-User Outlook** ## Market Drivers ### Growing Demand for Gene Therapies The increasing prevalence of genetic disorders and chronic diseases in the US is driving the demand for innovative treatment solutions. Gene therapies, which utilize viral vectors and plasmid DNA, are emerging as viable options for addressing these health challenges. The viral vectors-and-plasmid-dna-manufacturing market is witnessing a surge in demand, with estimates suggesting a growth rate of approximately 15% annually. This trend is likely to continue as healthcare providers and patients seek more effective therapies, thereby propelling the market forward. Furthermore, advancements in gene editing technologies, such as CRISPR, are enhancing the efficacy of these therapies, further stimulating interest and investment in the viral vectors-and-plasmid-dna-manufacturing market. ### Increased Focus on Preventive Medicine The shift towards preventive medicine is reshaping the landscape of healthcare in the US, with implications for the viral vectors-and-plasmid-dna-manufacturing market. As healthcare systems prioritize prevention over treatment, there is a growing interest in vaccines and gene therapies that can preemptively address diseases. This trend is likely to drive investments in the development of viral vectors and plasmid DNA technologies, as they play a crucial role in vaccine formulation. Market analysts suggest that this focus on prevention could lead to a market expansion of approximately 18% over the next few years, as more organizations recognize the potential of these technologies in combating infectious diseases and other health threats. ### Rising Investment from Venture Capital Venture capital investment in biotech is on the rise, particularly in the viral vectors-and-plasmid-dna-manufacturing market. Investors are increasingly recognizing the potential of gene therapies and related technologies, leading to a surge in funding for startups and established companies alike. This influx of capital is likely to drive innovation and accelerate the development of new products and services within the market. Recent data indicates that venture capital funding in the biotech sector has increased by over 30% in the past year, reflecting a strong belief in the future of the viral vectors-and-plasmid-dna-manufacturing market. As financial backing grows, so too does the potential for groundbreaking advancements in treatment options. ### Collaborations and Partnerships in Biotech Strategic collaborations between biotech firms and academic institutions are becoming increasingly common in the viral vectors-and-plasmid-dna-manufacturing market. These partnerships facilitate knowledge exchange and resource sharing, which can accelerate the development of new therapies. By pooling expertise and funding, stakeholders can enhance their research capabilities and bring innovative products to market more efficiently. The trend of collaboration is expected to contribute to a robust growth trajectory for the market, with estimates indicating a potential increase in market value by 25% over the next decade. This collaborative environment fosters innovation and positions the viral vectors-and-plasmid-dna-manufacturing market as a key player in the future of healthcare. ### Technological Advancements in Manufacturing Processes Innovations in manufacturing technologies are significantly impacting the viral vectors-and-plasmid-dna-manufacturing market. The introduction of automated systems and improved bioreactor designs is enhancing production efficiency and scalability. These advancements allow for higher yields and reduced costs, making it more feasible for companies to produce viral vectors and plasmid DNA at a larger scale. As a result, the market is expected to grow, with projections indicating a potential increase in market size by over 20% in the next five years. This technological evolution not only streamlines production but also ensures compliance with stringent regulatory standards, thereby fostering confidence among stakeholders in the viral vectors-and-plasmid-dna-manufacturing market. ## Future Outlook The [Viral Vectors and Plasmid DNA Manufacturing Market](https://www.marketresearchfuture.com/reports/viral-vectors-and-plasmid-dna-manufacturing-market-10679) is projected to grow at a 13.26% CAGR from 2025 to 2035, driven by advancements in gene therapy and biopharmaceuticals. **New opportunities:** - Development of customized viral vector platforms for targeted therapies. Expansion of contract manufacturing services for plasmid DNA production. Investment in automation technologies to enhance production efficiency. By 2035, the market is expected to achieve substantial growth, driven by innovation and increased demand. ## Segment Insights ### By Application: Gene Therapy (Largest) vs. Vaccine Development (Fastest-Growing) The application segment of the US viral vectors-and-plasmid-dna-manufacturing market is characterized by a diverse distribution of market share among several key areas. Gene therapy is the largest segment, driven by its increasing adoption in treating genetic disorders and chronic diseases. Following closely, vaccine development is gaining traction, particularly due to the ongoing need for rapid responses to emerging infectious diseases and the advancements in mRNA technologies. Growth trends within this segment indicate a robust expansion driven by technological advancements, increasing investment in R&D, and a surge in collaborations between biotech firms and academic institutions. The pandemic has catalyzed innovations in vaccine development, positioning it as the fastest-growing area. Moreover, regulatory support for gene therapies is strengthening the market, spurring growth across various applications. Gene Therapy: Dominant vs. Vaccine Development: Emerging Gene therapy is recognized as the dominant application within the US viral vectors-and-plasmid-dna-manufacturing market due to its pivotal role in addressing unmet medical needs in genetic diseases. It leverages advanced viral vector technologies that enable precise gene modification, showcasing significant efficacy and safety. In contrast, vaccine development has emerged as a vital area, propelled by the recent global health challenges that underscored the necessity for rapid vaccine production. This segment involves innovative techniques, particularly mRNA and viral vector platforms, to enhance immune responses. Both segments exhibit dynamic growth potential, influenced by ongoing research, increasing healthcare funding, and heightened public interest in advanced therapies. ### By Type: Viral Vectors (Largest) vs. RNA-based Vectors (Fastest-Growing) In the US viral vectors-and-plasmid-dna-manufacturing market, viral vectors currently dominate the landscape, securing a substantial share due to their applications in gene therapy and vaccine development. Plasmid DNA also maintains a notable position, primarily driven by its utility in DNA vaccines and therapeutic applications. Conversely, RNA-based vectors, although smaller in market share, are rapidly gaining traction, fueled by advancements in mRNA technology, which has been significantly accelerated by recent health challenges. The growth trajectory within this segment is being influenced by several factors, including increased investment in research and development, the emergence of new therapeutic areas, and the growing demand for innovative treatment solutions. As RNA-based vectors demonstrate their potential in vaccine formulations and other therapeutic uses, they are becoming increasingly important. The overall shift towards personalized medicine and the rise of genetic therapies are likely to drive further expansion in the US viral vectors-and-plasmid-dna-manufacturing market. Viral Vectors (Dominant) vs. RNA-based Vectors (Emerging) Viral vectors are recognized as the dominant player in this segment due to their established efficacy in delivering genetic material into target cells, notably in gene therapy applications. Their versatility and proven track record in clinical trials position them favorably among researchers and developers. On the other hand, RNA-based vectors, classified as emerging technologies, are experiencing accelerated growth driven by advances in mRNA therapeutic platforms. They offer unique advantages such as rapid development and the ability to elicit robust immune responses. As innovation continues, both segments are expected to evolve, with viral vectors maintaining a strong presence while RNA-based vectors carve out their niche in groundbreaking treatments. ### By Technology: Viral Transduction (Largest) vs. Electroporation (Fastest-Growing) In the US viral vectors-and-plasmid-dna-manufacturing market, Viral Transduction holds the largest market share due to its widespread application in gene therapy and vaccine development. Electroporation is emerging as a significant contender, attributed to its efficiency in delivering genetic material into cells, enhancing its adoption across various therapeutic areas. Other techniques like Microinjection and Liposomal Delivery continue to be relevant but do not match the prominence of these leading methods. The growth trends in this segment are driven by advancements in gene therapy and an increasing focus on personalized medicine. The demand for efficient and effective delivery methods has spurred innovation, leading to the development of technology like Electroporation, which is becoming the fastest-growing method. As awareness of genetic therapies expands, these delivery technologies will play a crucial role in shaping treatment outcomes. Technology: Viral Transduction (Dominant) vs. Electroporation (Emerging) Viral Transduction is a dominant technology in the US viral vectors-and-plasmid-dna-manufacturing market, known for its ability to deliver genetic material specifically and efficiently into target cells. This method is particularly favored in therapeutic applications for gene editing and vaccination strategies. On the other hand, Electroporation is an emerging technology characterized by its innovative approach to cell membrane permeabilization, allowing for increased uptake of plasmid DNA. This method is witnessing rapid adoption due to its potential in non-viral gene delivery systems, particularly in research and clinical applications. As the industry evolves, the demand for effective delivery mechanisms will likely result in further innovations within both technologies. ### By End-Use: Pharmaceutical Companies (Largest) vs. Biotechnology Firms (Fastest-Growing) In the US viral vectors-and-plasmid-dna-manufacturing market, the distribution of market share among key end-user segments is quite distinct. Pharmaceutical companies hold the largest market share, reflecting their extensive investment in developing gene therapies and advanced biologics. Conversely, biotechnology firms represent a rapidly growing segment, benefiting from increasing collaborations and innovations that enhance nucleic acid delivery systems. Growth trends for these segments are driven by rising demand for gene therapies and personalized medicine. Pharmaceutical companies continue to lead due to their robust pipelines and established production capabilities. In contrast, biotechnology firms are emerging as significant players, propelled by advancements in research and increasing R&D funding that fosters innovation, particularly in the development of cutting-edge biopharmaceuticals. Pharmaceutical Companies: Dominant vs. Biotechnology Firms: Emerging Pharmaceutical companies are the dominant end-user in the US viral vectors-and-plasmid-dna-manufacturing market, leveraging their extensive resources and established infrastructure to advance gene therapeutics. They prioritize high-quality manufacturing processes to ensure compliance with regulatory standards, thereby maintaining consumer trust and market share. On the other hand, biotechnology firms are seen as the emerging segment, characterized by agility and innovation. These firms often focus on specialized applications and are highly responsive to evolving market needs. As they develop novel therapeutic solutions, they are becoming increasingly competitive, driving partnerships and collaborations that enhance their capabilities in viral vector applications. ## Competitive Benchmarking The viral vectors-and-plasmid-DNA-manufacturing market is characterized by a dynamic competitive landscape, driven by advancements in gene therapy and vaccine development. Key players such as Thermo Fisher Scientific (US), Lonza Group (CH), and Merck KGaA (DE) are at the forefront, each adopting distinct strategies to enhance their market positioning. Thermo Fisher Scientific (US) focuses on innovation through its extensive portfolio of gene editing tools and services, while Lonza Group (CH) emphasizes strategic partnerships to bolster its manufacturing capabilities. Merck KGaA (DE) appears to be concentrating on expanding its product offerings in the plasmid DNA segment, thereby enhancing its competitive edge. Collectively, these strategies contribute to a robust competitive environment, fostering innovation and operational efficiency. In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. This trend is particularly evident in the US market, where firms are establishing facilities closer to key customers. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. Their collective actions shape the competitive dynamics, as they strive to meet the growing demand for viral vectors and plasmid DNA. In October 2025, Thermo Fisher Scientific (US) announced the opening of a new state-of-the-art facility dedicated to the production of viral vectors. This strategic move is likely to enhance their production capacity and meet the increasing demand for gene therapies. The facility is expected to leverage advanced technologies, positioning Thermo Fisher as a leader in the market and potentially increasing its market share. In September 2025, Lonza Group (CH) entered into a collaboration with a leading biotech firm to develop a novel plasmid DNA platform. This partnership is indicative of Lonza's commitment to innovation and could significantly enhance its product offerings. By aligning with biotech innovators, Lonza may strengthen its position in the market and drive future growth. In August 2025, Merck KGaA (DE) launched a new line of plasmid DNA products aimed at accelerating gene therapy development. This introduction reflects Merck's strategic focus on expanding its capabilities in the plasmid segment, which is crucial for the ongoing evolution of gene therapies. The launch is expected to attract a diverse clientele, further solidifying Merck's market presence. As of November 2025, the competitive trends in the viral vectors-and-plasmid-DNA-manufacturing market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve, shifting from price-based competition to a focus on technological advancements, innovation, and supply chain reliability. This transition underscores the importance of agility and responsiveness in a rapidly changing market. ## Recent News & Developments Recent developments in the US Viral Vectors and Plasmid DNA Manufacturing Market are characterized by significant growth and advancements. Companies such as Lonza and Merck have continued to expand their production capacities to meet the increasing demand for gene therapies and vaccines, particularly in light of the COVID-19 pandemic. In August 2023, Cobra Biologics announced the expansion of its facilities to enhance production capabilities for plasmid DNA, which is vital for mRNA vaccine development. In September 2023, Rentschler Biopharma completed the acquisition of a Canadian cGMP plasmid DNA production facility to bolster their offerings in viral vector manufacturing. Moreover, Amgen and Pfizer have been investing heavily in Research and Development efforts focused on novel therapies, resulting in an uptick in market valuation for firms engaged in this sector. Notably, regulatory frameworks in the US have evolved to streamline the approval processes for therapeutics, positioning the market for further growth. Over the last two to three years, major collaborations and public-private partnerships have also been fostered, enhancing innovation in gene therapy manufacturing, which is pivotal for addressing unmet medical needs. ## Report Scope | MARKET SIZE 2024 | 112.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 126.85(USD Million) | | MARKET SIZE 2035 | 440.7(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.26% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Lonza Group (CH), Sartorius AG (DE), Thermo Fisher Scientific (US), Merck KGaA (DE), Boehringer Ingelheim (DE), Cobra Biologics (GB), Viva Biotech (CN), GenScript Biotech (CN), Abcam plc (GB) | | Segments Covered | Application, Type, Technology, End-Use | | Key Market Opportunities | Advancements in gene therapy and personalized medicine drive demand in the viral vectors-and-plasmid-dna-manufacturing market. | | Key Market Dynamics | Technological advancements drive innovation in viral vectors and plasmid DNA manufacturing, enhancing therapeutic applications and market competitiveness. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the projected market valuation for the US viral vectors-and-plasmid-DNA-manufacturing market by 2035?** A: The projected market valuation is $440.7 Million by 2035. **Q: What was the overall market valuation in 2024?** A: The overall market valuation was $112.0 Million in 2024. **Q: What is the expected CAGR for the US viral vectors-and-plasmid-DNA-manufacturing market during the forecast period 2025 - 2035?** A: The expected CAGR is 13.26% during the forecast period 2025 - 2035. **Q: Which application segment is projected to have the highest valuation by 2035?** A: The Cell and Gene Editing application segment is projected to reach $140.7 Million by 2035. **Q: What are the key players in the US viral vectors-and-plasmid-DNA-manufacturing market?** A: Key players include Lonza Group, Sartorius AG, Thermo Fisher Scientific, and Merck KGaA. **Q: Which type of viral vector is expected to dominate the market by 2035?** A: Plasmid DNA is expected to dominate the market, projected to reach $200.0 Million by 2035. **Q: What is the projected valuation for the Vaccine Development application segment by 2035?** A: The Vaccine Development application segment is projected to reach $120.0 Million by 2035. **Q: Which technology segment is anticipated to show significant growth by 2035?** A: The Liposomal Delivery technology segment is anticipated to grow to $140.7 Million by 2035. **Q: What is the expected valuation for the Biotechnology Firms end-use segment by 2035?** A: The Biotechnology Firms end-use segment is expected to reach $120.0 Million by 2035. **Q: How does the market valuation in 2035 compare to that in 2024?** A: The market valuation in 2035 is expected to be significantly higher, increasing from $112.0 Million in 2024 to $440.7 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-viral-vectors-and-plasmid-dna-manufacturing-market-19752*